Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocon Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Long-Term Debt
â‚ą134.2B
CAGR 3-Years
62%
CAGR 5-Years
50%
CAGR 10-Years
33%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Long-Term Debt
â‚ą35m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Long-Term Debt
â‚ą50.8m
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Long-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Long-Term Debt
â‚ą1.6B
CAGR 3-Years
22%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Long-Term Debt
â‚ą209.9m
CAGR 3-Years
-69%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Long-Term Debt?
Long-Term Debt
134.2B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Long-Term Debt amounts to 134.2B INR.

What is Biocon Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
33%

Over the last year, the Long-Term Debt growth was -13%. The average annual Long-Term Debt growth rates for Biocon Ltd have been 62% over the past three years , 50% over the past five years , and 33% over the past ten years .

Back to Top